Ryan Dellinger
17Patents
3h-index
24Co-inventors
56Inventor score
Filing activity: May 8, 2012 → Aug 12, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10000520B2 | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | Chemistry; Metallurgy | 6 | Active |
| US10934322B2 | B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | Chemistry; Metallurgy | 4 | Active |
| US10183036B2 | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors | Human Necessities | 4 | Active |
| US10280190B2 | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions | Human Necessities | 2 | Active |
| US8841350B2 | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene | Human Necessities | 2 | Active |
| US12043616B2 | Crystalline forms of nicotinamide riboside chloride | Chemistry; Metallurgy | 2 | Active |
| US11389468B2 | Nicotinamide riboside for use in treating or preventing liver damage | Emerging Cross-Sectional Technologies | 1 | Active |
| US11414407B2 | Crystalline forms of nicotinamide riboside chloride | Chemistry; Metallurgy | 1 | Active |
| US10039725B2 | Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene | Human Necessities | 0 | Active |
| US11629163B2 | Methods of synthesizing nicotinamide riboside | Chemistry; Metallurgy | 0 | Active |
| US12350283B2 | Methods and compositions for treating motor neuron diseases | Human Necessities | 0 | Active |
| US9980924B2 | Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin | Human Necessities | 0 | Active |
| US11524022B2 | Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development | Human Necessities | 0 | Active |
| US11129843B2 | Treating and preventing kidney damage | Human Necessities | 0 | Active |
| US12128060B2 | Nicotinamide riboside for use in treating or preventing liver damage | Emerging Cross-Sectional Technologies | 0 | Active |
| US11730751B2 | Treating and preventing motor neuron diseases using nicotinamide riboside | Human Necessities | 0 | Active |
| US10857172B2 | Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.